CA-BOEHRINGER-INGELHEIM
9.1.2023 17:01:41 CET | Business Wire | Press release
Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining cancer cell-directed and immune cell-targeting compounds, further strengthening the company’s pipeline.
Cancer immunotherapies have brought dramatic breakthroughs, but only for a minority of cancer patients. 3T‘s platform aims to address this challenge by identifying novel shared T-cell receptor (TCR) targets of productive immune responses and comprehensively screening TCRs and TCR mimetics for specificity and off-target cross-reactivities. The platform identifies the most prevalent and immunogenic targets in solid tumors by uniquely combining high-diversity target libraries with active machine learning. This may lead to tumor-specific, safer therapies that can be delivered at higher doses.
“At Boehringer Ingelheim, we are committed to transforming patients’ lives. Through our new partnership with 3T Biosciences, we aim at accelerating and expanding our pipeline of first-in-class T-cell based therapies for patients affected by cancer,” said Lamine Mbow, Ph.D., Global Head of Cancer Immunology + Immune Modulation, Boehringer Ingelheim.
“On behalf of the entire team at 3T Biosciences, we are extremely pleased to partner with Boehringer Ingelheim, a company advancing transformative cancer treatments,” said Stefan J. Scherer, M.D., Ph.D., president and CEO of 3T Biosciences. “3T’s 3T-TRACE discovery platform has the potential to transform the treatment of cancers and beyond. By using data from patients for patients we aim to discover the best immunogenic targets for multiple tumor indications and across patient populations.”
Under the agreement, Boehringer Ingelheim will provide patient-derived TCR data to fuel 3T’s target discovery efforts to identify antigens using its 3T TRACE discovery platform. 3T will receive an upfront payment and research and development support, and is eligible for discovery, preclinical, clinical, regulatory, and commercial milestones totaling $268 million in addition to royalties on future Boehringer Ingelheim product sales. Boehringer Ingelheim is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement.
For the full press release and link to “Notes to Editors” please click here:
Press Release
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005420/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 202619.10.2026 00:05:00 CEST | Press release
Four rapid oral presentations at ESMO will feature new data for INCB161734, a KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibodyBoth investigational therapies are being evaluated in ongoing Phase 3 programsIncyte will host an investor event and webcast on Monday, October 26, 2026 from 7:30 – 9:00 CET / 2:30 – 4:00 p.m. ET Incyte (Nasdaq:INCY) today announced that it will present new data from its oncology portfolio during the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data being presented at ESMO further reinforce our confidence in these novel investigational approaches and their potential to improve and prolong the lives of patients with difficult-to-treat gastrointestinal cancers,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. “Importantly, these findings not only provide new clinical insights, but they also inform our registrational development programs
DCO Launches Second Edition of Digital Prosperity Awards to Recognize Solutions Building the Digital Future18.10.2026 20:35:00 CEST | Press release
The Digital Cooperation Organization (DCO) launched the second edition of the Digital Prosperity Awards (DPA), opening applications and nominations for eligible public-sector, private-sector and civil-society digital solutions across Member States and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261018682401/en/ DCO Launches Second Edition of Digital Prosperity Awards to Recognize Solutions Building the Digital Future (Photo: AETOSWire) The Awards recognize technology-driven solutions, initiatives and contributions delivering measurable socioeconomic impact, accelerating digital transformation and advancing an inclusive, sustainable and prosperous digital economy. The inaugural edition honored seven winners in February 2025. Ms. Deemah AlYahya, Secretary-General of the DCO, said: “A prosperous digital future is taking shape today through the vision, commitment and creativity of governments, innovators, organization
Andersen Global styrker sin skatterådgivning til privatkunder med KTA Tax17.10.2026 07:43:00 CEST | Pressemeddelelse
Andersen Global udvider sine skatterådgivningskompetencer inden for private client-området gennem en samarbejdsaftale med KTA Tax, en skattevirksomhed med base i Dublin, der har rådgivet enkeltpersoner og familier i næsten tre årtier. KTA Tax har rådgivet privatkunder og deres familier siden 1997 og forener den personlige tilgang fra et specialiseret rådgivningsfirma med indgående teknisk viden om irsk skatteret. Firmaets ydelser omfatter transaktions- og skatteplanlægning, generationsskifteplanlægning, investeringer og pensioner, internationale skatteforhold, sager hos skattemyndighederne, beskatning af løn og personalegoder samt årlig håndtering af personlige skatteforpligtelser. "Vi har hele tiden haft fokus på én ting: at yde klar og grundig skatterådgivning, der tager højde for vores kunder og deres familiers individuelle forhold," udtalte Lisa Cantillon, administrerende direktør for KTA Tax. "Samarbejdet med Andersen Global er et vigtigt skridt for KTA Tax. Det giver os mulighed
Abu Dhabi Launches TAMM Global to Bring Its AI-Native Government Platform to the World16.10.2026 16:00:00 CEST | Press release
Abu Dhabi has launched TAMM Global, a private technology company established to make the award-winning technology behind TAMM available to governments worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261016490320/en/ Abu Dhabi Launches TAMM Global to Bring Its AI-Native Government Platform to the World (Photo: AETOSWire) It is the first time the AI-powered platform, which serves 4.7 million users and is recognized as one of the world’s most advanced digital government platforms, will be available for international licensing and deployment. The launch marks a significant milestone in Abu Dhabi’s ambition to become the world’s first AI-native government. It reflects growing international demand for proven technologies that can accelerate digital transformation while protecting sovereignty, regulatory compliance and public trust. It also demonstrates how homegrown innovation and intellectual property are creating oppor
TestMu AI Brings Real Device Testing to Kane CLI, Letting Developers Test Mobile Apps on Real Phones From Any Terminal16.10.2026 16:00:00 CEST | Press release
Plain-English mobile tests now run on real Android and iOS devices in the TestMu AI cloud from any Mac, Windows, or Linux machine, with a live view of the device on the developer's laptop TestMu AI (formerly LambdaTest), the Full Stack Agentic AI Quality Engineering platform, announced real device support in Kane CLI. Developers can now test a mobile app on a real phone or tablet in the TestMu AI cloud straight from the terminal: they type what to test in plain English, and Kane taps through the app on a real Android or iOS device. Until now, testing a mobile app on real hardware meant keeping a drawer of phones, or a separate device farm outside the developer's workflow. With real device support, Kane CLI removes that dependency again now by giving terminal-first access to the real device cloud. Kane CLI on real devices gives teams: Real Android and iOS devices from any terminal. Kane CLI opens a real device in the TestMu AI cloud and taps through the app from natural language prompts
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom